| 摘要 |
<p>The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and/or endothelial cells, particularl y interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of a n effective amount of one or more agents that are antagonists of EphA2. In certain embodiments, the EphA2 antagonistic agent of the invention decreases EphA2endogenous ligand binding, upregulates EphA2 gene expression and/or translation, increases EphA2 protein stability or protein accumulation, decreases EphA2 cytoplasmic tail phosphorylation, promotes EphA2 kinase activity (other than autophosphorylation or ligandmediated EphA2 signaling), increases proliferation of EphA2 expressing cells, increases survival of Eph A2 expressing cells, and/or maintains/reconstitutes epithelial and/or endotheli al cell layer integrity. The invention also provides pharmaceutical composition s comprising one or more EphA2 antagonistic agents of the invention either alo ne or in combination with one or more other agents useful for therapy for a hypoproliferative cell disorder. Diagnostic methods and methods for screenin g for therapeutically useful agents are also provided.</p> |
